Idenix Pharmaceuticals, Inc. (IDIX) yesterday after market close announced results from an ongoing phase IIb study of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). Someone may be arguing about IDX184 efficacy judging by the number of trial patients that responded well to the initial treatment with a combination of IDX184, pegylated interferon, and […]